University spin-out secures £3.4M to advance 3D printed surgical implants

Nottingham-based 4D Medicine has secured £3.4 million in a Series A funding round to advance its innovative biomaterial for 3D printed implants and surgical devices. The company, a spin-out from the Universities of Birmingham and Warwick that was founded in 2020, is poised to make significant strides in medical technology.

4D Medicine has developed 4Degra, a resorbable biomaterial for implants such as orthopaedic devices and soft tissue scaffolds to aid patients recovering from surgery or injuries. The material can be 3D printed to create complex geometries and is versatile enough to be produced in both soft and hard formulations. This flexibility enables its use in a range of applications, from flexible films and membranes to rigid plates, pins, and bone scaffolds.

Philip Smith, the company’s chief executive, said: “I would like to thank all our investors for their trust and support. Our success in continuing to raise investment despite the difficult market conditions over the last few years is testament to their belief in the company’s commercial potential and our world-class team. The funds will be used to complete the pre-clinical testing of our first medical device product range and our preparations for entry into the orthopaedic market.”

The latest funding brings the total raised to date to £5m. The investment was led by Oshen Holdings, with backing from DSW Ventures, SFC Capital, Boundary Capital, and private investors, including several scientists and surgeons. This funding will allow 4D Medicine to complete pre-clinical testing of its initial product range and seek FDA clearance for entry into the US market.

Doug Quinn, partner at DSW Ventures, commented: “4D’s novel biomaterial platform opens up new possibilities for implants and devices. The company has already attracted attention from large industry players including a potential acquirer. This funding will enable it to apply for regulatory clearance in the US and target opportunities in the £5bn market for resorbable medical devices.”

4D Medicine is now preparing to raise a Series B investment early next year.